echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > Clin Trans Gastroenterology: Targeted albumin infusion does not improve systemic inflammation or cardiovascular function in decompensated cirrhosis

    Clin Trans Gastroenterology: Targeted albumin infusion does not improve systemic inflammation or cardiovascular function in decompensated cirrhosis

    • Last Update: 2022-05-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Numerous studies have shown that infusion of human serum albumin solution (HAS) restores normal blood volume and improves arterial dilatation in patients with cirrhosis and has potential immunomodulatory or anti-inflammatory properties in hospitalized patients with complications of cirrhosis Therefore, albumin infusion is recommended by all international guidelines


    Numerous studies have shown that infusion of human serum albumin solution (HAS) restores normal blood volume and improves arterial dilatation in patients with cirrhosis and has potential immunomodulatory or anti-inflammatory properties in hospitalized patients with complications of cirrhosis Therefore, albumin infusion is recommended by all international guidelines


    Vascular Statistics Infection

     

    The results of the study finally showed that the patient's end-stage liver disease score, white blood cell count, calprotectin level, CD163 level, tumor necrosis factor level, renin, and atrial natriuretic peptide levels were associated with increased 3-month mortality


     

    This study found that, contrary to many preclinical studies, targeted intravenous albumin therapy in hospitalized decompensated cirrhosis had no effect on broad systemic inflammation, albumin function, cardiovascular mediators, and biomarkers compared with standard care , which is consistent with previous clinical findings


    This study found that, contrary to many preclinical studies, targeted intravenous albumin therapy in hospitalized decompensated cirrhosis had no effect on broad systemic inflammation, albumin function, cardiovascular mediators, and biomarkers compared with standard care , which is consistent with previous clinical findings


    Original source:

    China, Louise.


    China, Louise.
    Et al.
    Targeted albumin infusions do not improve systemic inflammation or cardiovascular function in decompensated cirrhosis.
    Clinical and Translational Gastroenterology.
    2022.
    Targeted albumin infusions do not improve systemic inflammation or cardiovascular function in decompensated cirrhosis.


    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.